Literature DB >> 14332

High-dose treatment with neuroleptics in the acute phase of mental disease.

S J Dencker.   

Abstract

More than 300 patients have been observed during treatment with either flupenthixol, haloperidol, fluphenazine enanthate or perphenazine enanthate in high doses, whilst suffering from severe mental disease, usually of psychotic nature. Used correctly, high-dose treatment gives a rapid control of psychotic symptoms, an earlier discharge from the ward, and (when using long-acting neuroleptics) pharmacological control even during a follow up period. This means a social availability gain of 30-50%. We have not seen any severe somatic effects except those of parkinsonian type which can be treated successfully by the well trained psychiatrist and a skilled staff.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 14332      PMCID: PMC1863615     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


  3 in total

1.  Determination of perphenazine and fluphenazine in whole blood by gas chromatography.

Authors:  N E Larsen; J Naestoft
Journal:  Med Lab Technol       Date:  1973-04

2.  Prien RF, Cole JO: High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health--psychopharmacology research branch collaborative study group.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1968-04

3.  Very high dosage fluphenazine for nonchronic treatment-refractory patients.

Authors:  A Rifkin; F Quitkin; C Carrillo; D F Klein
Journal:  Arch Gen Psychiatry       Date:  1971-11
  3 in total
  2 in total

1.  Treatment of chronic schizophrenia.

Authors:  D A Johnson
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

2.  High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin.

Authors:  N Bjørndal; M Bjerre; J Gerlach; P Kristjansen; G Magelund; I H Oestrich; J Waehrens
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.